Daily Roundup

Resmed Reports Strong Q3 Results Driven by Dual Growth

Resmed Inc. is firing on all cylinders. The healthcare technology company posted net revenue of $1.41 billion in the third quarter, up 6.7% year-over-year, while net income surged 20.1% to $418.4 million. That translated to diluted earnings per share of $2.92, a solid performance that reflects the company's ability to expand margins even as it grows the top line.

The growth came from both of Resmed's main engines. Sleep and breathing health products contributed $1.26 billion in revenue, while its residential care software segment brought in $155 million. The company ended the quarter with $1.01 billion in cash, giving it a comfortable financial cushion. Looking ahead, Resmed is guiding for full-year revenue between $5.5 billion and $5.6 billion, with management anticipating continued momentum in both segments.

Pioneer Credit Locks in Major Bank Deal

Pioneer Credit Limited just scored a significant win. The debt management company has signed a three-year agreement with one of Australia's four major banks and has already completed its first acquisition under the deal. The portfolio purchase involved 17,000 customer accounts with a face value of approximately $206 million, acquired for $14.4 million. Active servicing kicks off in early February 2027.

What makes this noteworthy is Pioneer's unique position—it's now the only purchaser with agreements in place with each of Australia's four major banks. That's a meaningful competitive advantage as the company pursues a disciplined strategy focused on delivering appropriate outcomes for customers, banks, and shareholders alike.

Orthocell's U.S. Remplir Sales Hit New Heights

Orthocell Limited is seeing real traction in the U.S. market. The company reported its strongest month of sales for its nerve repair product, Remplir, since launch, moving 92 units in October and generating AU$279,000 in revenue. That represents an impressive 84% jump from the average monthly sales of 50 units during the first quarter of fiscal 2027.

The surge reflects growing surgeon adoption, increased repeat use, and a broader network of actively selling distributor representatives across key U.S. markets. The board remains confident in Remplir's significant market potential and the company's ability to translate expanding market access into sustained commercial success.

Emperor Energy Locks in Drilling Rig for 2027

Emperor Energy Ltd has taken a major step forward on its Judith-2 Appraisal Well project. The company executed a full form contract to secure the VALARIS 107 jack-up drilling rig, which will be available in April 2027 after completing current commitments in the offshore Gippsland Basin. Emperor has already paid $3.5 million upfront—comprising US$1.5 million from September and US$2.0 million upon contract execution—with additional payments due in 2027 prior to the rig's mobilization.

The drilling contract has a minimum duration of 30 days at an operating rate of US$165,000 per day. The Drilling Environmental Plan received NOPSEMA approval in late September, clearing another hurdle for the project.

Nodestream Advances International Expansion

Nodestream Ltd wrapped up a busy quarter with several strategic wins. The software company completed a $6.5 million placement and extended the maturity of its convertible notes by up to 12 months, bolstering its financial runway. On the business development front, Nodestream engaged Waypoint Strategic Partners for U.S. market entry and signed a non-binding MOU with a Ukrainian organization exploring potential defense applications.

The company also achieved a commercial launch of its Missions platform during the quarter. Revenue came in at $496,000, while the net operating cash outflow was $1.574 million. As of September 30, Nodestream held $2.765 million in cash and had $3.5 million in undrawn financing facilities available, positioning it to fund continued international expansion and product development.